Integrated management improves antiviral therapy outcomes in chronic hepatitis B patients with metabolic liver disease, suggesting better prognosis.
MASLD drives fibrosis and mortality in NA-treated CHB patients, as metabolic inflammation overrides the benefits of viral suppression. Integrated management, combining antiviral therapy, metabolic intervention, and immune monitoring, is essential to accurately assess progression and improve long-term prognosis.
No takes yet. Share an insight, caveat, or question.
Shiue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: